CD19-Targeting CAR T-Cell Therapy Shows Promise in Treating Systemic Sclerosis

This paper of the day published in Lancet Rheumatology demonstrates the potential of CD19-targeting CAR T-cell therapy in treating patients with diffuse systemic sclerosis. Systemic sclerosis is a rare autoimmune disease characterized by excessive fibrosis and inflammation in multiple organs. Despite advancements in treatment, many patients still experience significant disease progression and poor outcomes. Six patients with severe, treatment-resistant diffuse systemic sclerosis received CD19-targetting CAR T-cell therapy in this case series.  The results were promising, with no disease progression or significant adverse events observed. The therapy led to improvements in skin fibrosis, lung function, and other clinical manifestations. These findings suggest CD19-targeting CAR T-cell therapy could be a novel therapeutic approach for patients with severe systemic sclerosis. Further research is needed to confirm these results and explore this therapy's optimal dosing and timing.